Claims for Patent: 9,308,124

Summary for Patent: 9,308,124

Title:	Apparatus and methods for delivering therapeutic agents
Abstract:	In various embodiments, a drug-delivery device includes one or more reservoirs that may each contain a therapeutic agent for delivery to a patient.
Inventor(s):	Humayun; Mark (Glendale, CA), Caffey; Sean (Manhattan Beach, CA)
Assignee:	University of Southern California (Los Angeles, CA)
Application Number:	12/340,095
Patent Claims:	1. A method for treating an ophthalmic condition, comprising: implanting a drug-delivery device in a patient's eye, the device comprising (i) a refillable reservoir having a self-resealing upper layer that is pierceable by a needle for refilling and an opposed lower layer that is unpuncturable by the needle so as to protect the eye from injury, (ii) a tapered cannula in fluid communication with the reservoir, and (iii) a valve disposed in the cannula, wherein the valve controls fluid delivery, maintains a constant flow rate independent of variations in pressure driving a fluid flow through the cannula, and prevents backflow; and filling the reservoir with a liquid that comprises a therapeutic agent selected from the group consisting of acetazolamide, betaxolol, bevacizumab, bimatoprost, brimonidine, brinzolamide, carbidopa, carteolol, cidofovir, cyclosporine, dorzolamide, epinephrine, ketorolac tromethamine, ketotifen fumarate, latanoprost, levobetaxolol, levobunolol, levodopa, levofloxacin, loratadine, loteprednol etabonate, metipranolol, naphazoline, ofloxacin, pegaptanib, pemirolast, pheniramine maleate, pilocarpine, pseudoephedrine, ranibizumab, a steroid, timolol, travoprost, trifluridine, unoprostone isopropyl, valganciclovir, verteporfin, vitravene, a drug that prevents beta amyloid deposition in the retina, an anti-human complement activation blocker that blocks complement H activation in the eye, and siRNA molecules, wherein the device is implanted with the lower layer placed adjacent to the sclera of the eye and the cannula inserted into the eye through the sclera to facilitate delivery of drug from the reservoir into the eye. 2. The method of claim 1, further comprising directing the liquid to a target site via the cannula. 3. The method of claim 1, further comprising: (i) executing a stored drug-delivery regimen including a delivery pressure and a delivery flow rate of the liquid, (ii) receiving feedback from the patient, and (iii) modifying the stored drug-delivery regimen based on the feedback. 4. The method of claim 1, further comprising: (i) detecting the patient's position and activity; (ii) determining at least one of a frequency, time, or dosage of the liquid delivered to the patient based thereon; and (iii) responsively controlling delivery of the liquid. 5. The method of claim 4, wherein a dosage of the delivered liquid is controlled, at a constant flow rate, based on a duration that the liquid flows through the cannula.

Details for Patent 9,308,124

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2027-12-20
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	06/30/2006		2027-12-20
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	08/10/2012		2027-12-20
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	10/13/2016		2027-12-20
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	03/20/2018		2027-12-20